Trial Profile
Study to evaluate the Structural and Molecular brain changes and their correlation to clinical disability using [11C]PK11195 PET in Multiple Sclerosis patients and Healthy controls
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 26 Oct 2018
Price :
$35
*
At a glance
- Drugs Carbon-11 PK 11195 (Primary)
- Indications Multiple sclerosis
- Focus Diagnostic use
- 26 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis